L. Bergougnan

711 total citations
13 papers, 531 citations indexed

About

L. Bergougnan is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Psychiatry and Mental health. According to data from OpenAlex, L. Bergougnan has authored 13 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 5 papers in Cardiology and Cardiovascular Medicine and 4 papers in Psychiatry and Mental health. Recurrent topics in L. Bergougnan's work include Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Treatment of Major Depression (3 papers) and Schizophrenia research and treatment (3 papers). L. Bergougnan is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Treatment of Major Depression (3 papers) and Schizophrenia research and treatment (3 papers). L. Bergougnan collaborates with scholars based in France, United States and Netherlands. L. Bergougnan's co-authors include Fabrice Hurbin, P. Rosenzweig, M. Dubar, Frank LaCreta, Laurent Perrin, M. Canal, I. Zieleniuk, G. Bianchetti, Alain Patat and Dominick J. Angiolillo and has published in prestigious journals such as European Journal of Pharmacology, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

L. Bergougnan

13 papers receiving 496 citations

Peers

L. Bergougnan

CCM

PHARM

SURGE

PMH

EDM

Alin Andries Denmark

Alison N. Wadworth Switzerland

Feng Yu Kuo Taiwan

François Paillé France

Fran M. Gengo United States

P Imhof Switzerland

Pascal Daleau Canada

K. OʼMalley Ireland

D. Montero Spain

Joop C. van Oene Netherlands

Alin Andries Denmark

L. Bergougnan

210 ×0.8

CCM

146 ×1.2

PHARM

156 ×1.5

SURGE

70 ×0.8

PMH

48 ×0.6

EDM

Citations per year, relative to L. Bergougnan L. Bergougnan (= 1×) peers Alin Andries

Countries citing papers authored by L. Bergougnan

Since Specialization

Citations

This map shows the geographic impact of L. Bergougnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Bergougnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Bergougnan more than expected).

Fields of papers citing papers by L. Bergougnan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Bergougnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Bergougnan. The network helps show where L. Bergougnan may publish in the future.

Co-authorship network of co-authors of L. Bergougnan

This figure shows the co-authorship network connecting the top 25 collaborators of L. Bergougnan. A scholar is included among the top collaborators of L. Bergougnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Bergougnan. L. Bergougnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Bergougnan, L., Georg Golor, Fabrice Hurbin, et al.. (2020). First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection. British Journal of Clinical Pharmacology. 87(2). 598–611. 9 indexed citations

Moerland, Matthijs, Michiel J. B. Kemme, Anneke C. Dijkmans, L. Bergougnan, & Jacobus Burggraaf. (2011). Modulation of Vasoactivity and Platelet Aggregation by Selective 5-HT Receptor Antagonism in Humans. Journal of Cardiovascular Pharmacology. 58(6). 575–580. 16 indexed citations

Simon, Tabassome, Deepak L. Bhatt, L. Bergougnan, et al.. (2011). Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects. Clinical Pharmacology & Therapeutics. 90(2). 287–295. 69 indexed citations

Angiolillo, Dominick J., C. Michael Gibson, Shuk Han Cheng, et al.. (2010). Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clinical Pharmacology & Therapeutics. 89(1). 65–74. 214 indexed citations

Rosenzweig, P., M. Canal, Alain Patat, et al.. (2002). A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human Psychopharmacology Clinical and Experimental. 17(1). 1–13. 136 indexed citations

Legangneux, Eric, John McEwen, Keith Wesnes, et al.. (2000). The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. Journal of Psychopharmacology. 14(2). 164–171. 36 indexed citations

Dubruc, C., et al.. (1999). PK-PD relationship of the effects of argatroban on haemostasis in healthy young volunteers. Clinical Pharmacology & Therapeutics. 65(2). 151–151. 1 indexed citations

Bergougnan, L., et al.. (1998). Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. Human Psychopharmacology Clinical and Experimental. 13(7). 493–500. 10 indexed citations

Bergougnan, L., et al.. (1996). Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. European Neuropsychopharmacology. 6. S4–103. 1 indexed citations

10.

Rosenzweig, P., Steve Warrington, Alain Patat, et al.. (1993). Alpidem: Lack of sedative effect on psychomotor performance in therapeutic doses. Human Psychopharmacology Clinical and Experimental. 8(6). 409–415. 2 indexed citations

11.

Bergougnan, L., et al.. (1990). SL 84.0418: clinical and cardiovascular tolerance in healthy young volunteers off a new alpha 2 antagonist with anti-hyperglycaemic properties. European Journal of Pharmacology. 183(3). 1015–1016. 4 indexed citations

12.

Warot, D., L. Bergougnan, Denis Lamiable, et al.. (1987). Troleandomycin-triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation. European Journal of Clinical Pharmacology. 32(4). 389–393. 30 indexed citations

13.

Thuillez, Christian, et al.. (1985). ?-Adrenoceptor blocking effects and plasma levels of bornaprolol and propranolol in man. European Journal of Clinical Pharmacology. 29(4). 405–411. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact